Approved for use introgram/anabov. Owno uses 14031
U.S. Patient and Trademark Office DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10595308	
	Filing Date		2006-04-06	
	First Named Inventor Uwe		SCHON	
	Art Unit			
	Examiner Name			
	Attorney Docket Number	er .	B1180/20053	

U.S.PATENTS

Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue E	ate	Name of Patentee or Applicant of cited Document		Releva	Columns,Lines whe ant Passages or Rele s Appear	
	1	4566283		1986-0	1-28	BOESE				
	2	5003787		1991-0	4-02	ZLOBINSKY				
	3	5048300		1991-0	9-17	LIHL				
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner	Cite	Publication Number	Kind Code <sup>1</sup>	Publica	rtion	Name of Patentee or Applicant of cited Document			Columns, Lines whe	
Initial*	140		Code.	Date		of cited Docu	iment		s Appear	vanit
Initial*	1	20030029179	A1	2003-0	2-13	VANDERWO			s Appear	vanit
	1	20030029179 dd additional U.S. Publi	A1	2003-0		VANDERWO	UDE et al.	Figure		vant
	1		A1	2003-0	citatio	VANDERWO	UDE et al. please click the Ad	Figure		vant
	1 h to ac		A1	2003-0: plication FOREK	citatio	VANDERWOOD information p ENT DOCUM	UDE et al. please click the Ad	Figure:	Add	3 To

# | Application Number | 10595308 | Filing Date | 2006.04.06 | Filing Date | 2006.04.06 | Filing Date | 2006.04.06 | First Numeel Inventor | Use SCHON | Art Unit | Examiner Name | Attorney Docket Number | 81180200053 |

	2	4023573	DE	A1	1991-07-25	ZLOBINSKY			
	3	10229864	DE	A1	2003-03-27	WOUDE et al.			
If you wis	h to a	dd additional Foreign f	Patent Document	citation	information pl	ease click the Add buttor	Add		
	NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Initials*	ar Cite Noo include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazina, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Тs		
	1								
If you wis	h to a	dd additional non-pate	nt literature docu	ment cit	tation informati	on please click the Add I	button Add		
			EX	AMINE	R SIGNATUR	E			
Examiner	Signa	ture				Date Considered			
*FXAMIN	FR: In	itial if reference consid	dered whether or	not cits	ation is in confr	rmance with MPEP 609	Draw line through a		

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GQV">www.USPTO.GQV</a> or MPEP 801.04. 2 Enter office that issued the document, by the two-letter code (WIPO).

Nee And Code of USH IO Vasint biodimental sky <u>May USH TOSON</u> or the PS 913.8. Year for Code or USH IO Vasint biodimental sky <u>May USH TOSON</u> or the PS 913.8. Year for Code or the season of the USH or the Code or the Vasint State of the Same or the Code or the Vasint State or the Vasin

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10595308			
Filing Date		2006-04-06			
First Named Inventor Uwe		SCHON			
Art Unit					
Examiner Name					
Attorney Docket Number	er	B1180/20053			

### CERTIFICATION STATEMENT

Please see 37	7 CFR 1.	97 and	1.98 to make the	appropriate	selection(	s)
---------------	----------	--------	------------------	-------------	------------	----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(a)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(c).

- 7 See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- □ None

### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David M. Tener/	Date (YYYY-MM-DD)	2006-08-17
Name/Print	David M. Tener	Registration Number	37.054

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenan's Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.32.511.450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, V.32.311.450.

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.